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CON S E N S U S S T A T EM EN T
Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date infor-
mation on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection
of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the
process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such
evidence is inadequate or contradictory. A draft is prepared by the panel, followed by solicitation of input by the ACVIM membership which may
be incorporated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it is edited prior to publication. The
authors are solely responsible for the content of the statements.
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Abstract
Pulmonary hypertension (PH), defined by increased pressure within the pulmonary vascu-
lature, is a hemodynamic and pathophysiologic state present in a wide variety of cardio-
vascular, respiratory, and systemic diseases. The purpose of this consensus statement is
to provide a multidisciplinary approach to guidelines for the diagnosis, classification,
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treatment, and monitoring of PH in dogs. Comprehensive evaluation including consider-
ation of signalment, clinical signs, echocardiographic parameters, and results of other diag-
nostic tests supports the diagnosis of PH and allows identification of associated
underlying conditions. Dogs with PH can be classified into the following 6 groups: group
1, pulmonary arterial hypertension; group 2, left heart disease; group 3, respiratory dis-
ease/hypoxia; group 4, pulmonary emboli/pulmonary thrombi/pulmonary thromboemboli;
group 5, parasitic disease (Dirofilaria and Angiostrongylus); and group 6, disorders that are
multifactorial or with unclear mechanisms. The approach to treatment of PH focuses on
strategies to decrease the risk of progression, complications, or both, recommendations to
target underlying diseases or factors contributing to PH, and PH-specific treatments. Dogs
with PH should be monitored for improvement, static condition, or progression, and any
identified underlying disorder should be addressed and monitored simultaneously.
K E YWORD S
echocardiography, pulmonary arterial hypertension, respiratory disease, tricuspid regurgitation
velocity
1 | INTRODUCTION
This article is the report of the American College of Veterinary Internal
Medicine consensus panel on pulmonary hypertension (PH) in dogs. The
panel first established a working definition of PH and then proposed a clini-
cally applicable classification scheme for PH in dogs; with this framework as
the basis, practical guidelines for diagnostic, treatment, and monitoring rec-
ommendationswere developed. Pulmonary hypertension is not a single dis-
order, and a multidisciplinary approach is optimal. Therefore, the consensus
panel was comprised of board-certified specialists in the areas of internal
medicine, cardiology, emergency and critical care, diagnostic imaging, and
anatomic pathology. The panel initially met in person to outline overall
objectives and review the Delphi method1,2 for consensus building. Review
of the human and veterinary medical literature, development of electronic
revisions, and conference calls were used to draft the document and, using
amodification of theDelphimethod, build consensus for recommendations.
An advisory panel of 3 additional cardiologists helped develop echocardio-
graphic definitions of PH and guidelines for echocardiographic assessment
of PH. After development of a draft of the document, 2 additional advisory
panel members were included to provide input and rate each of diagnostic,
therapeutic, andmonitoring recommendations. The final tally of numbers of
panelists (out of 7) and outside experts (out of 5) agreeingwith each recom-
mendationwas noted,with comments to clarify reasons for any dissent.
2 | DEFINITION OF PH
2.1 | Hemodynamic definitions and terminology
Pulmonary hypertension is defined by abnormally increased pressure
within the pulmonary vasculature. The criterion standard method for diag-
nosis of PH is direct assessment of pulmonary arterial pressure (PAP) by
right heart catheterization (RHC) and, in humans, PH has been defined as
a mean PAP ≥25 mm Hg at rest.3 A schematic outlining the pathophysiol-
ogy of PH is shown in Figure 1. Increased PAP is not a defining character-
istic of a specific clinical condition but rather an abnormal hemodynamic
state associated with numerous, diverse disorders.4 Increased PAP, in the
absence of increased pulmonary vascular resistance (PVR), has several cau-
ses requiring different management strategies and having different out-
comes, including increased cardiac output, left-to-right shunts, and
increased pulmonary arterial wedge pressure (PAWP) secondary to the
left-sided heart disease (LHD). Increased PAP associated with increased
PAWP (>15 mm Hg in humans5; a surrogate for left atrial [LA] or left ven-
tricular filling pressure), is referred to as postcapillary PH. Postcapillary PH
occurs most commonly in dogs with LHD that have increased LA pressure.
It develops because LA hypertension increases the load on the right ventri-
cle and indirectly necessitates the development of higher systolic right
ventricular (RV) pressures. Chronic postcapillary PH can lead to pulmonary
arterial vasoconstriction and pulmonary vascular disease (PVD), which
increase PVR.6,7 Thus, postcapillary PH can occur in isolation (isolated
postcapillary PH [Ipost-PH]) or can occur together with increased PVR
(combined postcapillary and precapillary PH; C-PH) as a result of chronic,
progressive LHD. In humans, C-PH currently is defined by a pressure dif-
ference of ≥7 mm Hg between diastolic PAP and PAWP.5 An equivalent
pressure difference has not been established in dogs. Increased PAP also
can be caused by increased PVR and structural pulmonary arterial changes
associated with PVD due to a variety of other causes. Increased PAP asso-
ciated with increased PVR in the absence of increased LA pressure defines
precapillary PH (pre-PH).
3 | ECHOCARDIOGRAPHIC
ASSESSMENT OF PH
Echocardiography should be viewed as a clinical tool to help assess
the probability that a dog has PH, rather than a definitive diagnostic
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test for the presence of PH. Definitive diagnosis of PH requires RHC.
Echocardiographic assessment of PH is based largely on characteristic
cardiac changes that occur secondary to PH (ie, echocardiographic
signs of PH) and by estimating PAP from spectral Doppler tracings.
Because RHC rarely is utilized for definitive diagnosis of PH in dogs,
veterinarians rely on echocardiography for diagnosis, classification,
and management of dogs with PH.
However, clinicians should be mindful of limitations of
the echocardiographic examination (particularly Dopp-
ler echocardiography) and of inaccuracy,8 variability,
and imprecision9,10 potentially encountered when using
echocardiography to estimate PAP in individual dogs.
The panel has kept these echocardiographic shortcomings in mind
when proposing guidelines and recommendations. Because many echo-
cardiographic signs of PH have not been compared to RHC findings in
dogs, we have consulted current echocardiographic guidelines for
humans11,12 and the veterinary medical literature when relevant citations
were available to establish these guidelines. The proposed criteria are
intended to avoid misdiagnosis and inappropriate treatment of PH that
might have lasting impact on the dog and its owner. Lastly, echocardio-
graphic assessment of PH is just 1, albeit important, aspect in the overall
clinical assessment of a dog with suspected PH. Echocardiographic find-
ings always should be interpreted within the context of other clinical find-
ings, especially the presence or absence of clinical signs suggestive of PH
(Table 1) and right-sided heart failure status, as well as results of concur-
rent diagnostic testing.
3.1 | Echocardiographic signs of PH and
estimating PAP
The use of Doppler echocardiography to estimate PAP is crucial to the
echocardiographic assessment of dogs with suspected PH. Assuming the
F IGURE 1 Development of pulmonary hypertension, defined as abnormally increased pressure within the pulmonary vasculature, results
from increased pulmonary blood flow, increased pulmonary vascular resistance, increased pulmonary venous pressure, or some combination
thereof. Normal pulmonary vasculature is comprised of thin-walled arteries, veins and capillaries; a low pressure, low vascular resistance, and high
capacitance system. In homeostasis, blood ejected from the right ventricle (RV) into the pulmonary trunk is directed to the right and left
pulmonary arteries. The pulmonary arterial pressure remains low in homeostatic conditions by the dense network of pulmonary capillaries that
can accommodate rapid transit of large volume of blood arriving from the pulmonary arteries. Following efficient gas exchange at the alveolar-
capillary interface, oxygenated blood is then collected by the pulmonary venules that unite to form the veins, which eventually open into the left
atrium. Upon complex interactions of genetic and environmental factors, most of which are still poorly understood in dogs, homeostasis of
pulmonary circulation can be disturbed. These disturbances (summarized in boxes) can lead to an excessive increase in pulmonary blood flow,
increased pulmonary vascular resistance, or increased pulmonary venous pressure. Additionally, there is interplay between these factors*:
increased pulmonary blood flow or increased pulmonary venous pressure can lead to increased pulmonary vascular resistance due to pulmonary
arterial vasoconstriction, pulmonary vascular disease/remodeling, or both. When the average pulmonary arterial pressure increases above a
certain threshold (25 mm Hg is commonly used in humans), PH results. With sustained PH, the RV has to work harder against increases in
pulmonary pressures to move blood through the pulmonary vasculature. As a consequence, the RV undergoes structural alterations. Over time,
the progressive increase in RV workload can ultimately lead to RV dysfunction and failure, resulting in heart failure (ascites), low output signs, and
death. ASD, atrial septal defect; EDD, endothelial-dependent dilatation; LV, left ventricle; NO, nitric oxide; PDA, patent ductus arteriosus; PH,
pulmonary hypertension; VSD, ventricular septal defect
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absence of RV outflow tract obstruction (eg, pulmonary valve stenosis),
estimating systolic PAP involves quantifying peak tricuspid regurgitation
velocity (TRV), and then derivation of the pressure gradient (PG)
between the RV and right atrium using the simplified Bernoulli Equation
(PG = 4 × velocity [m/s]2). An estimate of right atrial (RA) pressure is
added to the calculated PG to yield estimated systolic PAP. Validated
methods to estimate RA pressure are unavailable in dogs, and therefore
estimates of RA pressure are arbitrary and potentially flawed.8,10,13 Con-
sequently, we recommend using only continuous wave Doppler measure-
ment of TRV (versus estimated systolic PAP) as a key metric in
determining PH probability as long as clinicians are aware that systolic
PAP might be underestimated when severe RA hypertension is present.
Measured TRV depends upon many factors including RV function and
pericardial restraint14 in addition to PAP and PVR. Additionally, poor
patient cooperation and labored respiration affect measurements. Accu-
rate interpretation of a TRV signal includes consideration of all factors
impacting RV systolic pressure. A pulmonary regurgitation (PR) jet also can
be used to estimate mean or diastolic PAP.11,15,16 Applying the simplified
Bernoulli equation to spectral Doppler measurements of peak diastolic PR
velocity provides an estimate of mean PAP.16 Similarly, peak diastolic PR
jet velocity offers an estimate of diastolic PAP after adding an estimate of
RA pressure.15 Because tricuspid regurgitation has been utilized more
commonly, and clinicians conventionally have viewed PH in relation to
estimates of systolic PAP, TRV can be considered the primary metric to
estimate PAP and the key component to determine the probability of PH
in at-risk dogs. Recommended echocardiographic criteria used to help
determine the probability of PH are presented in Table 2.
Although specific techniques of echocardiographic image acquisi-
tion and measurement are beyond the scope of this consensus state-
ment, Doppler spectra should be well visualized and their shape and
contour should comply with known hemodynamic principles. Care
should be taken to align the cursor parallel to the direction of flow,
TABLE 1 Clinical findings suggestive of pulmonary hypertension
(PH) in dogsa
Findings strongly
suggestive of PH
Findings possibly
suggestive of PH
Syncope (especially with exertion
or activity) without another
identifiable cause
Tachypnea at rest
Respiratory distress at rest Increased respiratory effort at rest
Activity or exercise terminating
in respiratory distress
Prolonged postexercise or
post-activity tachypnea
Right-sided heart failure
(cardiogenic ascites)
Cyanotic or pale mucous
membranes
aIt should be noted that none of these clinical signs are specific solely for
PH and therefore other causes of clinical signs are not excluded. Although
these clinical signs may be due to underlying respiratory disease, more
pronounced clinical signs reflect more severe disease, with more severe
disease likely to result in PH.
TABLE 2 Echocardiographic probability of PH in dogs
Peak tricuspid
regurgitation
velocity (m/s)
Number of different
anatomic sites of
echo signs of PHa Probability of PH
≤3.0 or not measurable 0 or 1 Low
≤3.0 or not measurable 2 Intermediate
3.0 to 3.4 0 or 1 Intermediate
>3.4 0 Intermediate
≤3.0 or not measurable 3 High
3.0 to 3.4 ≥2 High
>3.4 ≥1 High
aSee Table 3.
F IGURE 2 Example measurements of tricuspid regurgitation velocity (TRV) spectra acquired using continuous wave Doppler. A, The solid
arrow shows the recommended measurement of TRV. The dense outer edge of the velocity profile (brighter signal) is measured and measurement
sof the fine linear signals has been avoided. The dotted arrow represents a measurement that includes the fine linear signals or “feathered edge,”
which likely overestimates TRV. B, A TRV signal of good quality is shown. Notice the envelope is fully visible, the signal is not overgained (helps
to avoid fine linear signals), the sweep speed is increased, and the scale along the vertical axis is nearly filled by the TRV signal. C, Shows 3 TRV
signals, 1 of moderate quality (*) that is not completely filled in but can be measured by extrapolation and 2 others of poor quality (#) that are
unreliable and should not be measured
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optimize gain settings, and to measure regurgitant jets at the dense
outer edge of the velocity profile while avoiding measurement of fine
linear signals, also called the “feathered edge” (Figure 2).29-31 Because
tricuspid regurgitation jets can be eccentric, nonstandard imaging
planes might be necessary for visualization of tricuspid regurgitation
and acquisition of TRV.
In addition to TRV, several echocardiographic signs of PH aid prob-
ability assessment for PH. These signs involve 3 anatomic sites: (1) ven-
tricles, (2) pulmonary artery (although pulmonary artery is the
commonly used term in clinical practice, the preferred anatomic term
for the main pulmonary artery is pulmonary trunk32 and herein we con-
sider them synonymously), and (3) RA and caudal vena cava (Table 3).
These echocardiographic signs of PH largely involve assessment of the
ventricles (left ventricular and RV size and remodeling,19,21 systolic flat-
tening of the interventricular septum,17 and RV systolic func-
tion19,23-27,33), the pulmonary artery (pulmonary artery size17-19 and
flow profile,13,17,28,34), and the RA and caudal vena cava (RA19,21 and
caudal vena cava size19). Unfortunately, there is a lack of agreement on
how best to assess (ie, measure and quantify) these echocardiographic
variables in dogs with PH, and specific echocardiographic guidelines are
beyond the scope of this consensus statement.
3.2 | Echocardiographic probability of PH
with LHD
Recommendations in Tables 2 and 3 for echocardiographic assess-
ment of PH pertain to the use of a probability-based approach for
the assessment PH for all causes of PH (groups 1-6, Table 4). In
addition to criteria in Tables 2 and 3, identifying dogs with PH sec-
ondary to LHD requires fulfilling 2 additional echocardiographic
criteria: (1) documentation of LHD (eg, mitral or aortic valvular dis-
ease or left ventricular dysfunction) and (2) unequivocal LA
enlargement. Because RHC and PAWP determination are
performed rarely, LA enlargement is utilized as a crude, but robust,
surrogate for chronically increased PAWP and postcapillary PH. By
definition, patients with PH secondary to LHD must have
increased PAWP.5 The panel recognizes it is possible to encounter
acutely increased PAWP, and therefore iPost-PH secondary to
LHD without LA enlargement caused by, for example, ruptured
chordae tendineae in a dog with myxomatous mitral valve disease
(MMVD). Sonographers should be cognizant of this uncommon
exception. Chronically increased PAWP is a necessary component
of clinically relevant C-PH secondary to LHD.5,6 In other words, it
is less likely for PH, and particularly C-PH, to be secondary to LHD
unless unequivocal LA enlargement also is identified. Echocardio-
graphic signs of PH such as decreased LV size or LV underfilling
are not applicable to dogs with PH secondary to LHD because of
the confounding effects of LV remodeling secondary to LHD. In
dogs with PH secondary to LHD, criteria proposed in Tables 2 and
3 for high probability of PH are more likely to identify patients
with C-PH. This approach is supported by clinical studies of dogs
with MMVD demonstrating the clinical and prognostic relevance
of TRV >3.5-3.7 m/s.82,152
3.3 | Proposed clinical definition of PH
In the veterinary medical literature, the degree or severity of PH has
been classified as mild, moderate, or severe. These categories are based
on the PG derived from TRV (also called the tricuspid regurgitation PG)
or estimated systolic PAP. Cutoffs used for these categories (mild, mod-
erate, severe) are arbitrary, and the categories are potentially misleading
or flawed. For example, based on the conventional definition of PH
(based solely on estimated systolic PAP), a dog with severe PH can be
free of clinical signs, whereas a dog with moderate PH could be in right-
sided heart failure. Therefore, the panel does not advocate their use.
Instead, severity of PH should be based on clinical findings (Table 1) and
TABLE 3 Anatomic sites of echocardiographic signs of PH used to help assess the probability of PH in dogs
Anatomic site 1: Ventricles Anatomic site 2: Pulmonary artery
Anatomic site 3: Right atrium and
caudal vena cava
Flatting of the interventricular
septum (especially systolic
flattening)
Pulmonary artery enlargement
(PA/Ao >1.017,18)
Right atrial enlargement19,20
Underfilling or decreased size of
the left ventriclea
Peak early diastolic PR velocity >2.5 m/s Enlargement of the caudal vena
cava19
Right ventricular hypertrophy (wall
thickening, chamber dilation, or
both)19,21
RPAD index <30%17,22
Right ventricular systolic
dysfunction19,23-27
RV outflow Doppler acceleration time
(<52-58 ms) or acceleration time to ejection
time ratio (<0.30)17,18,28
Systolic notching of the Doppler RV outflow
profile (caution: false positives are possible)
Abbreviations: PR, pulmonary regurgitation; RPAD, right pulmonary artery distensibility; RV, right ventricular.
aNot applicable for dogs with group 2 PH due to the confounding effects of LV remodeling secondary to LHD.
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outcome data from large (prospective) longitudinal studies, which unfor-
tunately are unavailable. The panel recognizes the probabilistic approach
to diagnosis of PH presents challenges, particularly regarding
standardized enrollment in future clinical studies of dogs with suspected
PH. Therefore, we propose that the clinical definition of PH should
include dogs with intermediate or high probability of PH, and specifically,
TABLE 4 Proposed classification of pulmonary hypertension in the doga
1. Pulmonary arterial hypertension
1a. Idiopathic (IPAH)35-39,b; 40-45,c
1b. Heritable46,47
1c. Drugs and toxins induced48,49,d
1d. Associated with (APAH):
1d1. Congenital cardiac shunts17,18,35,41-43,46,47,50-75
1d2. Pulmonary vasculitis63,71,76-78
1d3. Pulmonary vascular amyloid deposition79
10. Pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH)80,81,e
2. Pulmonary hypertension due to left heart disease
2a. Left ventricular dysfunction
2a1. Canine dilated cardiomyopathy18,25,35,43,50,51
2a2. Myocarditis35
2b. Valvular disease
2b1. Acquired
2b1a. Myxomatous mitral valve disease10,13,17,18,20,24,25,34,35,41-43,50-52,82-89
2b1b. Valvular endocarditis
2c1. Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
2c1a. Mitral valve dysplasia18,52
2c2a. Mitral valve stenosis90
2c3a. Aortic stenosis43
3. Pulmonary hypertension secondary to respiratory disease, hypoxia or bothf
3a. Chronic obstructive airway disordersg
3a1. Tracheal or mainstem bronchial collapse18,85,91
3a2. Bronchomalacia91-93
3b. Primary pulmonary parenchymal disease
3b1. Interstitial lung disease (reviewed in94,95)
3b1a. Fibrotic lung disease18,28,40,91,92,96
3b1b. Cryptogenic organizing pneumonia/secondary organizing pneumonia97
3b1c. Pulmonary alveolar proteinosis98
3b1d. Unclassified interstitial lung disease (ILD)41,66,85,91,99,100
3b1e. Eosinophilic pneumonia/eosinophilic bronchopneumopathy66,92,101
3b2. Infectious pneumoniah: Pneumocystis91,102,103; Ehrlichia?104,105
3b3. Diffuse pulmonary neoplasia35,66,85,91,92,106
3c. Obstructive sleep apnea/sleep disordered breathing107,108,d; 91,92,109,i
3d. Chronic exposure to high altitudes110-112
3e. Developmental lung disease91
3f. Miscellaneous: bronchiolar disorders91; bronchiectasis91; emphysema91,113; pneumonectomy114
4. Pulmonary emboli/thrombi/thromboemboli (PE/PT/PTE)115-121
4a. Acute PE/PT/PTE8, 122-125,d
(Massive PE/PT/PTE with RV dysfunction or submassive PE/PT/PTE without RV dysfunction)
4b. Chronic PE/PT/PTE126,d,40
5. Parasitic disease (Dirofilaria or Angiostrongylus infection17,25,35,41,44,50,51,66,127-147)j
(Continues)
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a tricuspid regurgitation PG cutoff of >46 mm Hg (TRV >3.4 m/s). This
roughly equates to what has been conventionally referred to as at least
moderate PH. Until there are echocardiographic variables that are
repeatable and have acceptable diagnostic accuracy relative to RHC, this
cutoff value could be usedwith an understanding of its limitations.
4 | COMPREHENSIVE CLINICAL
ASSESSMENT FOR PH
Diagnosis of PH requires comprehensive evaluation including consid-
eration of signalment, clinical signs, echocardiographic parameters
supporting PH, and results of other diagnostic tests. Clinical signs
reflect the degree of functional impairment and can be used to iden-
tify dogs with clinical signs that are strongly or possibly suggestive of
PH (Table 1). Attributing clinical signs directly to PH can be challeng-
ing or impossible because of underlying disease that may dominate
the clinical picture.
4.1 | Clinical presentation
In dogs, PH occurs as a primary pulmonary vascular disorder or as a
sequela to other cardiac, respiratory, or systemic diseases. Signalment,
TABLE 4 (Continued)
6. PH with multifactorial or unclear mechanismsk
6a. Disorders having clear evidence of 2 or more underlying groups 1-5 pathologies contributing to PHl
6b. Masses compressing the pulmonary arteries (eg, neoplasia, fungal granuloma, etc.)
6c. Other disorders with unclear mechanisms
aGiven the limitations of the veterinary literature (eg, single case reports or small case series, retrospective study design, frequent presence of confounding
comorbid conditions contributing to PH, lack of uniform and rigorous diagnostic testing to definitively rule out comorbid conditions, among others), not all
panelists agree with provided references to support the disease as the cause of PH. Larger, prospective carefully designed studies will be required to
provide the necessary evidence to further refine this classification scheme.
bIn the veterinary literature, when no underlying cause of PH has been found, PH is often assumed to be “idiopathic.” However, it is important to recognize
the difference between not finding a cause after an exhaustive diagnostic evaluation and calling a disease idiopathic after a cursory evaluation (see Figures 3–
7). The first 5 references are considered definitive studies as histopathology documents a pulmonary arteriopathy in the absence of a known cause.
cThe next 6 references are considered questionable support for IPAH; although no identified cause was found, the diagnostic evaluation may not have
been reported or have been incomplete and histologic evaluation was not performed.
dExperimental canine studies.
ePVOD and PCH can occur in tandem.
fIn the peer-reviewed veterinary literature, many studies refer to “chronic respiratory/pulmonary disease” or “idiopathic” respiratory disease, or “chronic
tracheobronchial disease” without definitive documentation of the specific underlying disorder.35,40-42,66,85,149 Other listed “definitive” diagnoses may be
published without ruling out disease mimics in an exhaustive fashion (eg, thoracic radiography alone can be definitive for collapsing trachea but
nondefinitive for bronchomalacia or fibrotic lung disease). Without a criterion standard definitive confirmation (eg, bronchoscopy for bronchomalacia or
lung biopsy for pulmonary fibrosis), many of these respiratory diseases are likely inadequately characterized. Additionally, many dogs with disorders
associated with PH in humans do not get a specific evaluation for PH; thus the group 3 disorders are likely grossly underestimated. Additionally, disorders
which are not clearly documented or are undocumented to cause PH in the dog include pharyngeal collapse,150 laryngeal collapse, laryngeal paralysis, and
epiglottic retroversion.
gAlthough “chronic bronchitis” has been listed as a diagnosis in some canine reports,18,85 this syndrome alone in the dog is unlikely to cause PH. The term
chronic obstructive pulmonary disease (COPD) used in humans encompasses underlying and overlapping conditions such as chronic bronchitis and
emphysema. Both cause airflow limitation and dyspnea in people. Canine chronic bronchitis by itself (ie, without concurrent bronchomalacia) does not
cause airflow limitation leading to increased expiratory respiratory effort and emphysema is very rare in dogs, thus the term COPD is inappropriate to use
in this species. Tracheal and mainstem bronchial collapse and bronchomalacia are common causes of obstructive airway disorders; however, referenced
studies proving they cause PH are somewhat limited by many reported dogs having comorbid conditions also known to cause PH.
hAngiostrongylus and Dirofilaria are excluded from infectious causes of pneumonia as the pathophysiology of PH is usually multifactorial with these
parasitic infections. The term “pneumonia” by itself does not necessarily imply an infectious etiology and care must be taken when interpreting results of
studies that do not specifically identify an organism but find compatible radiographic changes or inflammatory cells on airway lavage or
histopathology.35,51,66 These cases may represent ILDs.
iBrachycephalic obstructive airway syndrome is listed under obstructive sleep apnea/sleep disordered breathing as the dog is a model for human disease.151
However, as this is a heterogeneous syndrome with multiple defects, clinical manifestations could also be classified under chronic obstructive airway disorders.
jDirofilaria and Angiostrongylus have been associated with endarteritis,17,25,35,41,44,50,51,66,127-142 PE/PT/PTE,147 inflammatory pulmonary parenchymal
disease,143-146 or all, as their mechanisms of PH.
kIn humans, hematologic disorders (eg, certain types of anemia, myeloproliferative disorders, and splenectomy), systemic disorders with lung involvement
(eg, sarcoidosis, Langerhans cell histiocytosis, vasculitis, etc), metabolic disorders (disorders of impaired cell metabolism, thyroid disease), and other
diseases not well classified in another group (eg, compressive lesions such as lymphadenopathy, tumor or fibrosing mediastinitis obstructing the pulmonary
arteries, etc) comprise the multifactorial, unclear mechanism group, or both.148 As these analogous disorders with rare exception either do not occur in
dogs or if they occur, may not be documented to cause PH, additional research and modification of these group 6 disorders in dogs will likely be needed.
This is a particularly poorly understood category and it is likely that other diseases will be added in the future with additional investigation.
lTo be classified as 6a, there must be identified diseases in more than 1 of the group 1-5 disorders (eg, group 2 MMVD and group 3b1 ILD) and not just 2
or more types of disease within a single disorder (group 3a1 tracheal collapse and group 3b1a fibrotic lung disease).
REINERO ET AL. 555
history, and clinical presentation can reflect the underlying cause. Congen-
ital cardiac shunts and developmental lung disease are generally
manifested in puppies, whereas acquired cardiac, respiratory, and systemic
diseases usually present in adults. Dogs with MMVD and PH usually are
older small breed dogs.18,35,50,51,109 A breed predisposition for PH second-
ary to interstitial lung disease has been suggested inWest HighlandWhite
Terriers28 and Pekingese dogs.99 Historical data supporting exposure to
Dirofilaria or Angiostrongylus in endemic regions warrant careful scrutiny
for these parasites. Exertional syncope, labored respiration or overt respi-
ratory distress, and exercise intolerance are noteworthy clinical signs fre-
quently directly attributable to PH.40,52,153,154 Cough is commonly
reported but more likely reflects an underlying respiratory disease.35 Car-
diac auscultation may identify heart murmurs localized to the mitral valve,
tricuspid valve or both; a diastolic heart murmur of PR occasionally is
detected in patients with severe PH.52 A split or loud second heart sound
may be auscultated, particularly with severe PH.154 A right-sided systolic
murmur,155 right-sided heart failure (eg, a distended abdomen caused by
cranial organomegaly or ascites), or both may be detected. Jugular vein
distention and pulsation may be present. Cyanosis may occur secondary
to primary pulmonary disease or congenital cardiac disease exhibiting
right-to-left pulmonary-to-systemic shunting. Evaluation of the breathing
pattern (increased inspiratory effort, increased expiratory effort, mixed
inspiratory/expiratory effort, or paradoxical breathing pattern) may pro-
vide clues to an underlying airway, parenchymal or pleural cavity disorder,
especially when paired with audible noises present with or without the
use of a stethoscope.156 Pulmonary auscultation may identify muffled
sounds, crackles, wheezes, or increased bronchovesicular sounds. Crackles
may indicate interstitial lung disease (especially fibrotic lung disease),
severe bronchomalacia, or pulmonary edema or exudate.94,157,158
5 | CLASSIFICATION OF PH
In dogs, the prevalence of PH is as yet unknown. There appears to be
increased awareness of PH, likely because of increased recognition of
clinical signs of PH and underlying disorders that have PH as a comor-
bid condition and more widespread availability of echocardiography.
Historically, LHD (eg, MMVD) had been among the most commonly
identified causes of PH.7,13,18,35,41,42,50-52,83,109,152,159 However,
many disorders causing PH may go unrecognized, especially when
echocardiography is not performed or when clinical signs attributable
to the primary disease dominate the clinical picture.
Wepropose 6 groups of PH in dogs, loosely following the classification
scheme used in humans with modifications148 subdivided to reflect similar
themes in some or all of the following: cause of PH, clinical presentation,
hemodynamic characteristics, pathophysiology, and treatment. Such a clas-
sification is intended to improve diagnostic evaluation and optimize thera-
peutic management of dogs with PH. Finally, classification into well-
defined groups should facilitate future clinical studies.160 As in humans, it is
expected that evolution of this classification scheme will occur with
increased recognition and understanding of underlying conditions.
The proposed clinical classification of PH in dogs comprises the fol-
lowing 6 groups (Table 4): Group 1, pulmonary arterial hypertension
(PAH); group 2, LHD; group 3, respiratory disease/hypoxia; group
TABLE 5 Terminology, hemodynamic definitions, and echocardiographic findings of PH together with the proposed clinical classification
groups of pulmonary hypertension
Terminology
Hemodynamic definition
by right heart catheterization
used in humans
Echocardiographic
findings
Clinical classification
group
Precapillary PH Mean PAP ≥25 mm Hg No left atrial enlargement Group 1. Pulmonary arterial
hypertensiona
PAWP ≤15 mm Hg At least some findings listed in
Table 3 are expected
Group 3. PH due to respiratory disease/
hypoxia
Increased PVR Group 4. Thromboembolic PH
Group 5. Parasitic disease
Group 6. PH with multifactorial and/or
unclear mechanisms
Postcapillary PH Mean PAP ≥25 mm Hg Left atrial enlargement Group 2. PH due to left heart disease
PAWP >15 mm Hg Group 6. PH with multifactorial and/or
unclear mechanismsIsolated postcapillary PH DPG <7 mm Hg Left atrial enlargement
PVR not increased
Combined postcapillary
& precapillary PH
DPG ≥7 mm Hg Left atrial enlargement
Increased PVR At least some findings listed in
Table 3 are expected
Abbreviations: DPG, diastolic pressure gradient (diastolic PAP − mean PAWP); PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge
pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance.
aCongenital cardiac shunts (group 1d1) exhibiting left-to-right shunting represents an exception. The PH may be primarily due to increased right heart
cardiac output and not increased PVR.
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4, pulmonary emboli/pulmonary thrombi/pulmonary thromboemboli
(PE/PT/PTE); group 5, parasitic disease (Dirofilaria and Angiostrongylus);
and group 6, disorders that are multifactorial or with unclear mechanisms.
Peer-reviewed references to support the classification are provided when
possible, with the caveat that studies describing a diagnosis of a particular
disease in a dog with PH do not necessarily prove that the disease caused
PH. Refinement of this classification scheme will likely be needed in the
future. When >1 possible cause for PH is present, consideration must be
given to the likelihood that each individual underlying cause is contributing
to PH. If the contribution to PH from a comorbid condition is minimal, PH
should be classified according to the major disease, however, if there
potentially are substantial contributions from ≥2 comorbid conditions,
they should be placed in group 6, encompassing multifactorial mecha-
nisms. For example, a dog with MMVD without LA enlargement and
severe interstitial lung diseasewould be classified as group 3b1; a dogwith
stage C MMVD161 and severe interstitial lung disease would be classified
as group 6a. This discrimination is important because group 6 disorders
are likely to require multimodal treatment targeted at each underlying
pathologic mechanism. The group 5 classification for PH in dogs repre-
sents the largest deviation from the human medical literature, because
humans are not affected by PH secondary to Dirofilaria or Angiostrongylus
infection. Table 5 provides a summary of terminology, hemodynamic defi-
nitions, and echocardiographic findings of PHwith the corresponding pro-
posed clinical classification of PH.
6 | GUIDELINES FOR DIAGNOSTIC
EVALUATION OF DOGS WITH
SUSPECTED PH
6.1 | General comments
Pulmonary hypertension is not a disease per se but rather a hemo-
dynamic and pathophysiologic state present in a wide variety of
diseases.53,154 Diagnostic testing in suspected cases thus must
encompass 2 major goals: (1) to assess the probability of PH using
echocardiography and (2) to determine the underlying cause of PH
when possible. This information is critical to best guide therapeu-
tic recommendations. In practice, there are 2 pathways of diag-
nostic evaluation for PH in dogs. The first involves dogs
presenting with a spectrum of clinical signs in which diagnostic
testing targets identification of a primary cause of disease, with
PH considered later in the evaluation. Consensus diagnostic rec-
ommendations D1-D7 below are guidelines for when to pursue
echocardiography to assess the probability of PH based on other
test results. The second approach involves early assessment of the
probability of PH using echocardiography. Because some clinicians
identify intermediate or high probability of PH based on sugges-
tive clinical signs, with echocardiography performed early in the
diagnostic evaluation (specifically to investigate PH or for other
reasons such as a heart murmur), diagnostic algorithms to help
determine the underlying cause of PH (ie, groups 1-6) also are pro-
vided (Figures 3–7).
6.1.1 | Consensus recommendations for PH
diagnosis
D1. Echocardiography to assess the probability of PH should be consid-
ered as an early diagnostic test in dogs with clinical findings suggestive
of PH (Table 1)35,36,51,80,99,109,162 after physical examination and tho-
racic imaging rule out another specific disorder not associated with PH.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
D2. Echocardiography to assess the probability of PH should be
considered when thoracic radiography shows evidence of tortuous,
blunted, or dilated pulmonary arteries; asymmetric radiolucent lung
fields on dorsoventral or ventrodorsal views; patchy, diffuse alveolar
infiltrates40; a bulge in the region of the pulmonary trunk or right-
sided cardiac enlargement.52,154,163
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
D3. Echocardiography to assess the probability of PH should be
considered in dogs with clinical signs suggestive of PH (Table 1) and
having ascites (modified transudate with noncardiac causes ruled out),
a dilated caudal vena cava on point-of-care ultrasound (POCUS; dia-
phragmaticohepatic view) or a dilated caudal vena cava and hepatic
veins on abdominal ultrasonography.
• Consensus in 6/7 members of the panel and 4/5 advisory reviewers
• Comment: One panelist recommended caution in interpretation of
POCUS right-sided cardiac markers (eg, large caudal vena cava,
hepatic venous distension, ascites or gall bladder wall edema)
because they had poor utility for discrimination of dogs with and
without PH.164 One advisory reviewer recommended the removal
of POCUS from D3 stating assessment of the caudal vena cava is
challenging, subject to intra- and inter-individual variation and
complicated by operator experience, patient positioning, and
equipment.
D4. Echocardiography to assess the probability of PH may be con-
sidered in dogs having spent time in endemic areas and that are, or
have a history of, confirmed Dirofilaria positivity165 or Angiostrongylus
positivity162 with clinical signs (eg, for heartworm disease: coughing,
respiratory distress, collapse, anemia, hyperbilirubinemia, exercise intol-
erance or ascites; for angiostrongylosis: cardiac, respiratory, or neuro-
logic signs or bleeding diathesis) or thoracic radiographic abnormalities
(eg, right-sided heart enlargement; enlarged pulmonary trunk; enlarged,
blunted, or tortuous pulmonary arteries; or pulmonary infiltrates)
suspected in association with these parasites.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
Dogs with a condition associated with acute or chronic PE/PT/PTE
are at risk for PH. Examples include immune-mediated hemolytic ane-
mia, spontaneous hyperadrenocorticism, protein-losing nephropathy,
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protein-losing enteropathy, sepsis, neoplasia, and disseminated intra-
vascular coagulation.115-119,166-168 Additionally, although heartworm
disease and angiostrongylosis cause PH by multifactorial mechanisms,
an important contributor to increased PAP is parasitic embolism.
D5. Echocardiography to assess the probability of PH should be
considered in dogs at high risk169 for PE/PT/PTE that have developed
clinical signs suggestive of PH particularly with evidence of hypoxemia
and thoracic imaging that fails to identify another underlying cause for
the respiratory signs.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
Thoracic computed tomography (CT) is a highly sensitive imaging
modality. Especially when incorporated with single or multi-phase
angiography, thoracic CT can provide supportive or definitive evi-
dence for PVDs, pulmonary parenchymal diseases, and PE/PT/PTE,
many of which can be associated with PH.
D6. If not already performed, echocardiography to assess the
probability of PH should be considered when thoracic CT angiography
shows ≥1 of the following:
a. A pulmonary trunk-to-descending aorta ratio ≥1.4170
b. Evidence of RA and RV enlargement
c. A decreased pulmonary vein-to-PA ratio; an increased pulmonary
trunk-to-ascending aorta ratio, or an increased RV-to-LV ratio92
d. The presence of pulmonary arterial filling defects171
e. A mosaic attenuation pattern showing small vessels in a region of
decreased attenuation (ie, hypoperfusion) on an inspiratory scan
that fails to show accentuation of the mosaic attenuation pattern
on an expiratory scan (ie, ruling out air trapping)172
f. Perivascular diffuse nodular to ill-defined patchy ground-glass opacity
with a global distribution, compatible with pulmonary capillary
hemangiomatosis (PCH) or pulmonary veno-occlusive disease (PVOD)80
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
• Comments: Although measurement of RV173,174 (and perhaps RA)
enlargement evaluated on contrast CT scan is suspected to be a viable
metric for PH, peer-reviewed studies in dogs with PH have not yet
been published. Additionally, signalment and physical examination
should be used to discriminate dogs with pulmonary valve stenosis
that also may have findings a-c above.
F IGURE 3 Algorithm demonstrating the overall diagnostic approach to the 6 groups of pulmonary hypertension in which echocardiography
performed early in the clinical evaluation identifies intermediate or high probability PH. In addition to determining an intermediate or high
probability of PH, echocardiography can also be used to support, confirm, or refute pathology in group 1d1, group 2, group 4, and group 5. The
order in which diagnostic algorithms should be consulted are group 3 (Figure 4) and group 4 (Figure 5) with group 5 potentially being identified on
this initial algorithm or within the group 3 algorithm. The group 1 algorithm (Figure 7) generally used after ruling out disorders in groups 2-6.
Critical to appropriate use of the diagnostic algorithms is the understanding that dogs frequently have greater than 1 type of pathology
contributing to PH either across groups (eg, a dog with MMVD with interstitial lung disease is encompassed in groups 2 and 3, respectively) or
within a group (eg, a dog with tracheal collapse and fibrotic lung disease both fall within group 3). Clinical evaluation must drive the diagnostic
approach and make sense in context of localizing disease and pursuit of comorbid conditions. For example, a small breed dog with left-sided heart
failure that has inspiratory stridor in addition to rapid, shallow breathing should not have the diagnostic algorithm terminated after diagnosis of
group 2c1a disease; instead, further evaluation for an upper airway defect such as extrathoracic tracheal collapse should be pursued. aThoracic
radiographs are frequently obtained before echocardiography and may provide additional findings supportive of underlying PH etiology.
bEvidence of an in situ PT in the main pulmonary artery may be noted on echocardiographic examination. LHD, left-sided heart disease; PH,
pulmonary hypertension, PT, pulmonary thrombus
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Although performed uncommonly as a primary diagnostic test for
pulmonary disease, lung biopsy specimens may be acquired and sub-
mitted for histologic examination and can be very valuable in identify-
ing and characterizing vascular pathology.
D7. Echocardiography to assess the probability of PH should be
considered when histologic examination indicates evidence of wide-
spread PVD:
a. The use of routine hematoxylin and eosin staining can help eluci-
date the pathogenesis of PAH. Examples of vascular lesions include
arterial or arteriolar medial smooth muscle hypertrophy or hyper-
plasia, pulmonary arterial intimal hyperplasia or fibrosis, vascular
thrombosis, or occlusion, and arterial plexiform lesions. Large num-
bers of hemosiderophages may indicate pulmonary venous hyper-
tension. Increased numbers of alveolar capillary endothelial cells
suggest PCH or potentially severe pulmonary venous hypertension
associated with markedly increased LA pressures.
b. Verhoeff-Van Gieson staining is a valuable additional technique
that assists in distinguishing arteries and veins and can be very
helpful in identifying affected veins in PVOD.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
• One panelist commented that adequately large lung biopsy specimens
and multiple (>2) lung biopsies may be needed to characterize the
underlying disease process. The absence of lesions especially in small
biopsy specimens or in end-stage tissue (ie, fibrosis) may not allow the
elimination of vascular pathology as a possibility. Additionally, the
pathologist evaluating the lesions must be knowledgeable
about PVDs.
7 | TREATMENT
Treatment of PH can be subdivided into strategies to decrease the
risk of progression or complications (treatment consensus state-
ments T1a-e), recommendations to target underlying diseases or fac-
tors contributing to PH (treatment consensus statements T2-T12),
and PH-specific treatments (treatment consensus statements
T13-T24).
Interpretation of therapeutic recommendations is dependent
on the level of evidence, degree of clinical impairment, and echo-
cardiographic probability of PH. The strength of the recommenda-
tion is higher when the primary literature is available regarding
treatment of dogs with spontaneous PH (aside from single case
reports) or, in the absence of these data, strong expert opinion, and
the treatment statements are worded as “recommended.” When
recommendations are extrapolated from humans, canine models, or
weaker anecdotal experience of experts, the treatment statements
are worded as “may be considered.” As reviewed in Tables 1 and 2,
clinical findings are stratified as strongly or possibly suggestive of
F IGURE 4 Diagnostic algorithm for discrimination of group 3 respiratory disease/hypoxia in dogs. Proper interpretation relies on
confirmation that the comprehensive clinical picture can be explained solely by the “final diagnosis” (bold boxes); otherwise, continue to evaluate
for PH in other subcategories of group 3 and in groups 1, 4, 5, and 6. BAL, bronchoalveolar lavage; CT, computed tomography; FNA, fine-needle
aspiration; HW, heartworm; I/E, paired inspiratory/expiratory series; MSB, mainstem bronchial; OSA, obstructive sleep apnea; PAH, pulmonary
arterial hypertension; PH, pulmonary hypertension; PTE, pulmonary thromboembolism
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PH and echocardiographic evidence of PH as low, intermediate, or
high probability.
7.1 | Strategies to decrease the risk of progression
or complications of PH
T1. Several guidelines yet untested in randomized clinical trials, seem
prudent, especially in dogs with high probability of PH:
a. Exercise restriction
b. Prevention of contagious respiratory pathogens using vaccina-
tion175 and parasitic disease (eg, Dirofilaria and Angiostrongylus)
control using chemoprophylaxis in endemic areas
c. Avoidance of pregnancy (because of potential to exacerbate PH
and because of the possibility of transmission of genetic
contributors)
d. Avoidance of high altitude and air travel
e. Avoidance of nonessential wellness procedures (eg, dental
cleanings) and elective surgery requiring general anesthesia
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.2 | Recommendations to target underlying
diseases or factors contributing to PH
Long-term supplemental oxygen has yet to be evaluated as supportive
treatment using randomized clinical trials in people with PH but gen-
erally is recommended.12 A recent large observational study showed
benefit in PAH.176 At home, oxygen treatment is feasible in dogs and
could be considered, especially if there appears to be a positive clinical
response. Additional studies are warranted.
7.2.1 | Group 1 PAH
For the majority of group 1 dogs, there is no effective primary treat-
ment and PH-specific treatment is the major means of management
(see T13-T15 below).
T2. Shunt closure or occlusion is recommended in dogs in group 1d1,
provided the shunt is hemodynamically relevant (ie, cardiac remodeling is
present or likely to develop) and the shunt is exclusively from left to right
or becomes so upon administration of pulmonary vasodilators.
T3. It is recommended that dogs in group 1d1 exhibiting right-
to-left shunting and having erythrocytosis and clinical signs be
F IGURE 5 Diagnostic algorithm for discrimination of group 4 pulmonary emboli/thrombi/thromboemboli in dogs. Proper interpretation relies
on confirmation that the comprehensive clinical picture can be explained solely by the “final diagnosis” of PE/PT/PTE; otherwise, continue to
evaluate for PH in groups 1 and 6. aRisk factors include but are not limited to hypercoagulability (eg, CBC, serum biochemical profile, UA, UP:C,
TEG, D-dimers), pulmonary arterial mass, endothelial injury (eg, IV catheter, polytrauma with immobility), and evidence of air or fat emboli. bIdeally
triphasic angiography is recommended. cVentilation-perfusion scans using nuclear scintigraphy can also be used to document PE/PT/PTE but are
not commonly performed. CT, computed tomography; PH, pulmonary hypertension, UA, urinalysis; UP:C, urine protein:creatitine ratio; TEG,
thromboelastography
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F IGURE 6 Diagnostic algorithm for determination of group 6 (multifactorial and/or unclear mechanisms) in dogs. Confirm that the
comprehensive clinical picture can be explained solely by the “final diagnosis” (bold boxes). Otherwise, consider hematologic, systemic, and
metabolic disorders of unclear mechanism that have been identified in humans with PH148 and if not present or likely to be causative of PH,
continue to evaluate for PH in group 1. Each disease identified must be addressed in the overall treatment plan. aEach will need to be addressed
independently when considering optimal treatment. CT, computed tomography; HW, heartworm; LHD, left heart disease; PA, pulmonary artery;
PH, pulmonary hypertension; PE/PT/PTE, pulmonary emboli/thrombi/thromboemboli
F IGURE 7 Diagnostic algorithm for discrimination of group 1 pulmonary arterial hypertension in dogs. The approach to group 1 disorders
generally requires ruling out groups 2-6 disorders first. Importantly, histologic changes associated with the pulmonary vasculature in group 1a-c
are not pathognomonic and can occur secondary to primary cardiac and respiratory disease. Histopathology can provide definitive diagnosis for
group 1d2, 1d3, and 10 disorders. aExtrapolated from humans; not definitively proven for canine PVOD/PCH. bConfirmed on histopathology.
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension, PDE5, phosphodiesterase 5; PVOD/PCH, pulmonary veno-occlusive
disease/pulmonary capillary hemangiomatosis
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treated by periodic phlebotomy, typically with fluid replacement.54
Hydroxyurea can be considered as an alternative to decrease red cell
volume.177
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.2.2 | Group 2 PH secondary to LHD
Treatment strategies for targeting the underlying disease in group
2 patients are centered around identifying and, if possible, reversing
the cause of LHD, decreasing postcapillary PH (ie, lowering LA pres-
sure) and, if present, treating heart failure. Management strategies for
specific LHD and left-sided heart failure (LHF) are beyond the scope
of this consensus statement. However, readers are encouraged to
consult the ACVIM consensus guidelines for the management of
MMVD,161 which includes management strategies for LHF and pre-
clinical MMVD treatment, and the veterinary literature evaluating
pharmacotherapy to delay the onset of heart failure in dogs with com-
mon LHD such as MMVD178,179 and dilated cardiomyopathy.180
T4. Because dogs with PH secondary to LHD, by definition, have
postcapillary PH (with or without pre-PH), the use of phosphodiester-
ase 5 inhibitors (PDE5i) is not recommended as first line treatment.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.2.3 | Group 3 PH secondary to respiratory
disease, hypoxia, or both
Group 3 dogs have diverse respiratory diseases, and an exhaustive
discussion of specific treatments is beyond the scope of this consen-
sus statement. Treatment of the underlying respiratory disorder
should decrease the severity of clinical signs, improve the perceived
quality of life, and attenuate, halt, or delay the progression of pathol-
ogy leading to further impairment in respiratory function.
T5. General strategies of value that are recommended include
weight loss in obese patients, environmental modifications to improve
air quality and optimize humidity, and reduction of recognized triggers
of clinical signs. In obese patients, weight loss can decrease clinical signs
by increasing thoracic wall compliance and decreasing extrathoracic and
intra-abdominal adipose tissue.181 Although not documented in dogs to
date, morbid obesity may cause severe but reversible PH in
people,182,183 underscoring its importance in the general management
strategy. Environmental changes, reduction of specific triggers of bar-
king, anxiety, and excitement, as well as the use of a harness instead of a
neck collar can help decrease the stimulus to cough.184
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
T6. In group 3a disorders, recommended treatment is primarily
symptomatic and includes cough suppression, sedation, oxygen sup-
plementation, and, when present, control of secondary infection and
inflammation. Specific examples may include, but are not limited to,
glucocorticoids, opioids or other sedatives, antimicrobials, and antitus-
sives.181,185-188 For management of severe tracheal collapse, place-
ment of an intraluminal stent can be considered.189,190
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
T7. The group 3b disorders are diverse, some with specific treat-
ments and some in which viable treatment options do not exist.
a. Within group 3b1, fibrotic lung disease to date has no effective
treatments, likely reflecting end-stage lesions and lack of under-
standing of specific triggers.94,158 In some cases of fibrotic lung dis-
ease, PO or inhaled corticosteroids may relieve cough, particularly
in the presence of concurrent bronchial changes.191,192 Dogs with
cryptogenic organizing pneumonia receiving early and aggressive
treatment with immunosuppressive doses of glucocorticoids may
have a good prognosis.94 Whole lung lavage has been described to
treat pulmonary alveolar proteinosis.193 Corticosteroids are the pri-
mary treatment for eosinophilic lung disease.95,185,186
b. In dogs with group 3b2 disorders in which infection underlies
pathology, appropriate antimicrobials are recommended. For exam-
ple, pneumocystis pneumonia should be treated with high-dose
trimethoprim-sulfonamide with or without an anti-inflammatory
dose of corticosteroids.102,194
c. In dogs with group 3b3 diffuse pulmonary neoplasia, consultation with
a veterinary oncologist is recommended because options are limited
and for most cancers (aside from lymphoma), and prognosis is grave.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
T8. In group 3c, dogs with brachycephalic obstructive airway syn-
drome (BOAS) and other causes of upper airway obstruction that have
been less clearly documented to cause PH, early recognition and med-
ical or surgical management is recommended. In BOAS, the upper air-
way obstruction components that can be surgically corrected (eg,
elongated soft palate, stenotic nares, aberrant rostral and caudal turbi-
nates, everted saccules) should be surgically treated early in life to
minimize the progression of clinical signs and avoid possible develop-
ment of PH.195-199 Although the link to development of PH is unclear,
concurrent management of alimentary tract disease contributing to
respiratory disease is prudent, even in the absence of overt dysphagia,
vomiting, and regurgitation.198,200
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.2.4 | Group 4 PH secondary to PE/PT/PTE
Treatments for underlying causes of PE/PT/PTE are beyond the scope
of this consensus statement and are reviewed elsewhere.201 A recent
consensus statement on the rationale use of antithrombotics is
relevant.202
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T9. In dogs with PH caused by suspected or confirmed PE/PT/
PTE, prompt treatment with antithrombotic agents should be insti-
tuted. Heparin (low molecular weight or unfractionated) and PO direct
anticoagulants (eg, rivaroxaban, apixaban) may be preferred over PO
antiplatelet agents (eg, clopidogrel, aspirin).
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
T10. In dogs with PH caused by acute PE/PT/PTE and having
overt RV dilatation and systolic dysfunction associated with systemic
hypotension and collapse, immediate use of systemic or local tissue
plasminogen activator (with or without concurrent endovascular or
surgical thrombectomy) may be considered, with an understanding of
the potential risks and appropriate access to intensive 24-hour
monitoring.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.2.5 | Group 5 PH secondary to parasitic disease
(Dirofilaria or Angiostrongylus infection):
T11. The reader is referred to guidelines for management of heart-
worm disease165 and angiostrongylosis.203
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.2.6 | Group 6 PH with multifactorial or unclear
mechanisms
Treatment of the group 6a disorders should focus on identifying and
addressing individual pathology contributing to PH when possible (see
above recommendations).
T12. When feasible in group 6b dogs, medical, endovascular, or
surgical treatment to address the compressive mass lesion (eg, treat-
ment of blastomycosis, radiation therapy for heart base masses, intra-
vascular stents) is recommended.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.3 | PH-specific treatment
Excessive pulmonary arterial vasoconstriction secondary to a variety
of pulmonary arterial endothelial insults develops via the nitric oxide,
endothelin, or prostacyclin pathways.204 In people, recommendations
for PH-specific treatment focus on maximizing vasodilatory response
by targeting multiple pathways concurrently. In dogs, initial simulta-
neous targeting of all pathways is uncommon because of the lack of
evidence, feasibility, cost, and quality of life issues with repeated med-
ication administration. In dogs, the first-line treatment of PH consists
of PDE5i that specifically target and augment the vascular nitric oxide
pathway. The PDE5i are intended to target pre-PH by decreasing
PVR. Dose escalation of PDE5i or other PH-specific medications may
be considered if the patient becomes refractory and if severe clinical
signs warrant more aggressive treatment.
Most of the peer-reviewed veterinarymedical literature regarding dogs
with PH has evaluated the PDE5i, sildenafil.40,42,43,52,80,84,205-207 These
studies suggest benefit with improvement of clinical signs,52 quality of
life,52,84,207 exercise capacity,84 and decreased echocardiographically-
estimatedPAPcomparedwith baseline,42,84,207 but TRVmight not decrease
after PDE5i treatment despite observed clinical benefits.52 This outcome
may occur because pulmonary blood flowmight increase as PVR decreases,
thus resulting in little change in PAP. Additionally, aforementioned limita-
tions of echocardiography to estimate PAP also may play a role. Sildenafil
has a short half-life, ideally necessitating q8 hour dosing,208,209 which repre-
sents a disadvantage. Rectal administration of sildenafil can be considered
when PO dosing is not feasible.209 More recently, tadalafil has emerged as
an appealing alternative210 with a longer half-life, allowing for q24h dosing,
improved compliance and, in some cases, lower cost. In a randomized
double-blinded study comparing sildenafil and tadalafil in dogs with PH,
PDE5 inhibition was safe and improved quality of life without demonstrat-
ing superiority of 1 PDE5i over the other.210
Treatment strategies for PH are highly dependent on cause and
chronicity of PH. Some PH-specific treatments (eg, pulmonary artery
vasodilators such as PDE5i) might lead to acute pulmonary edema in
some dogs with PH. Therefore, pulmonary artery vasodilators in some
specific situations such as dogs with PH associated with congenital car-
diac shunts (group 1d1) or secondary to LHD (group 2) warrants caution.
In dogs with PH associated with congenital cardiac shunts, increased
PAP can be caused primarily by increased blood flow through the pulmo-
nary vasculature, reactive pulmonary vasoconstriction, or may occur sec-
ondary to PVD.Often it is difficult using echocardiography to discern the
relative impact of each of these factors on estimated PAP. Dogs in group
1d1 without substantially increased PVR exhibit left-to-right (systemic-
to-pulmonary) shunting and will benefit from closure or occlusion of the
shunt rather than a pulmonary artery vasodilator. Dogs in group1d1with
increased PVRmight benefit from a pulmonary artery vasodilator, partic-
ularly if they are exhibiting bidirectional or right-to-left (pulmonary-to-
systemic) shunting and erythrocytosis. Closure will not be possible if
PVR exceeds systemic vascular resistance. In some cases, shunt flow
may reverse (ie, become left-to-right) after administration of a pulmonary
artery vasodilator, thus permitting safer closure or occlusion of the
shunt.55 However, a pulmonary artery vasodilator might induce pulmo-
nary edema in some dogs in this scenario if they have “reactive” or
“responsive” pulmonary arteries (or arterioles) and substantial irrevers-
ible PVD has not developed.
Similarly, dogs in group 2 may (C-PH) or may not (Ipost PH) have
increased PVR (Table 5). In addition to treatment specifically targeting
the LHD and LHF, some dogs with C-PH might benefit from a PDE5i
in an attempt to alleviate clinical signs. However, similar to dogs in
group 1d1, their vascular reactivity or responsiveness to a pulmonary
vasodilator is difficult to predict, and pulmonary edema also may
ensue. The mechanism of inducing pulmonary edema is similar in dogs
in groups 1d1 and 2. In both situations, a pulmonary artery vasodilator
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might increase right heart cardiac output, acutely increasing pulmo-
nary venous return to the LA and subsequently increase LA and thus
pulmonary venous and capillary pressures, resulting in pulmonary
edema. In scenarios in which a PDE5i is initiated (see below), close
monitoring for development of pulmonary edema is strongly rec-
ommended. Ideally, such monitoring should be done in a veterinary
hospital. Resting or sleeping respiratory rate and effort should be
closely monitored. Pulmonary edema should be ruled out (eg, by tho-
racic radiography) if sleeping or resting respiratory rates are consis-
tently >30-40 breaths/min211,212 or if respiratory distress is observed.
Because of the risk of inducing pulmonary edema in this context,
some clinicians advise starting with a conservative dosage of pulmo-
nary vasodilator medications (eg, sildenafil 0.5 mg/kg PO q8h).
Unless otherwise stated, consensus recommendations
for PH-specific treatment below assume that clinical
findings suggestive of or associated with PH are appar-
ent (Table 1) and the proposed clinical definition of PH
has been fulfilled, that is, intermediate or high probabil-
ity of PH is present (Tables 2, 3).
The panel does not advocate PH-specific treatment in dogs with-
out clinical signs or findings suggestive of PH.
7.3.1 | Group 1 PAH
Insufficient data are available in the veterinary medical literature to
follow consensus recommendations for humans. In treatment-naive
humans, management begins with acute vasoreactivity testing (gener-
ally using a short acting vasoactive agent such as nitric oxide) to deter-
mine the likelihood of response to initial therapeutic trials.213
Empirical treatment is advocated in dogs.
T13. A PDE5i is recommended for group 1a, 1b, and 1c because
without treatment the prognosis is guarded to grave and no specific
treatment is available for underlying disease. Anecdotal experience
suggests a subpopulation of dogs with suspected group 1a-c disorders
may have a good clinical response to sildenafil.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
Dogs with group 1 PAH associated with occlusive cellular or
fibrotic vascular occlusive lesions or both (ie, group 1d2, 1d3, and
10) may have a lesser contribution from defects in vasomotor tone.
Once PH has been diagnosed, patients with these disorders tend
to have short survival periods, no cure and poor response to typi-
cal PH-specific treatments. A lack of clinical trials assessing treat-
ment response is challenging because these diseases are rare,
advanced, and frequently lack a definitive antemortem diagnosis.
T14. Using PDE5i in dogs with group 1’ disorders may result in
fatal acute pulmonary edema as seen in some humans; this may occur
because higher blood flows are not accommodated by the fixed
downstream obstruction in the veins, capillaries, or both. Although
insufficient evidence of a similar phenomenon exists in the veterinary
medical literature,80 the recommendation is that PDE5i be initiated in
the hospital in dogs with known or suspected PVOD and PCH, with
close monitoring for development of acute pulmonary edema. The
drug should be withdrawn immediately if this complication occurs.
Because PVOD and PCH are most likely to be definitively diagnosed
postmortem, a high index of suspicion antemortem will be required to
maintain appropriate vigilance.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
In dogs in group 1d1 exhibiting right-to-left (pulmonary-to-sys-
temic) shunting, morbidity and mortality generally are thought to be
linked to effects of chronic hypoxemia and erythrocytosis rather than
heart failure. The use of PDE5i may attenuate both PH and clinical
signs and help manage secondary erythrocytosis.206 In the panelists'
experience, survival of dogs with right-to-left shunting is highly vari-
able, and untreated dogs have been observed to remain free of clinical
signs and survive for prolonged periods of time.
T15. A PDE5i may be considered in dogs in group 1d1 exhibiting
bidirectional or right-to-left shunting in an attempt to improve clinical
signs and help manage erythrocytosis. In this scenario, hematocrit
might serve as an objective variable to monitor response to the
PDE 5i. In-hospital monitoring when PDE 5i treatment is initiated is
advisable for the reasons discussed above.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.3.2 | Group 2 PH secondary to LHD
Treatments for pre-PH (ie, pulmonary artery vasodilators) in people with
LHD are controversial and not routinely advised because of the risk of
adverse events and lack of compelling data showing benefit.214 Although
addressing the underlying LHD or LHF is most important, PH-specific
treatment in dogs with group 2 disease may be considered as adjunctive in
selected cases in an attempt to alleviate clinical signs. The following recom-
mendations assume cardiogenic pulmonary edema has been ruled out (eg,
by thoracic radiography) because a PDE5i should be administered only to
dogs free of acute or decompensated LHF (cardiogenic pulmonary edema).
T16. Heart failure medications (HFM) and a PDE5i are rec-
ommended for dogs with clinical (eg, jugular venous distension, fluid
wave on abdominal palpation, or auscultable pleural fluid line) and ultra-
sonographic (abdominal or pleural effusion without another cause along
with RA enlargement, caudal vena caval distension, hepatic venous dis-
tension or hepatomegaly) evidence of right-sided heart failure.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
T17. Addition of a PDE5i may be considered in dogs with exer-
tional syncope without another identifiable cause that have failed to
respond to other treatments for preclinical LHD (eg, pimobendan).
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• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
T18. A PDE5i may be considered for dogs with a high probability of
PH with compensated LHF (ie, dogs previously diagnosed with LHF and
on HFM but that do not currently have pulmonary edema) that develop
cardiogenic ascites. Treatment should be carried out by up-titration of
HFM to offset the potential risk of inducing pulmonary edema.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
T19. A PDE5i may be considered for dogs with compensated LHF
and a high probability of PH (ie, dogs previously diagnosed with LHF
and on HFM but that do not currently have pulmonary edema) that
develop exertional syncope without another identifiable cause. A thor-
ough diagnostic evaluation is advised to rule out alternative causes of
syncope (eg, ECG, ambulatory ECG monitoring, or both to exclude
bradyarrhythmias or tachyarrhythmias as potential causes for syncope).
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.3.3 | Group 3 PH secondary to respiratory
disease, hypoxia, or both
In people, for the same reasons noted for group 2 PH, the use of PH-
specific treatments for group 3 PH are not routinely recommended.214
In contrast, in dogs with group 3 PH, there may be benefit to addi-
tional PH-specific treatment during or after treatment for underlying
pulmonary disease. In a recent study of dogs with diverse causes of
group 3 PH, administration of PDE5i was the only independent pre-
dictor of survival in a multivariable analysis.91
T20. A PDE5i is recommended in group 3 dogs.40,42,52,84,205,210
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.3.4 | Group 4 PH secondary to PE/PT/PTE
In a canine model of acute pulmonary embolism, sildenafil decreased
mean PAP and blunted decreases in PaO2.
215 Sildenafil has been used
rarely in people with acute pulmonary embolism leading to PH, despite
showing benefit.216-218 The PH classification scheme used in humans
focuses on chronic thromboembolic PH, in which PH-specific treat-
ments are indicated in patients who are not surgical candidates for end-
arterectomy, if preoperative hemodynamic stabilization is needed and if
signs persist or recur after surgery.214 In dogs with acute and chronic
group 4 PH, additional PH-specific treatment can be considered during
or after treatment directly targeting underlying causes of PE/PT/PTE.
T21. Although only experimental evidence in a canine model sup-
ports the use of sildenafil in acute PE, PDE5i may be considered in
group 4a patients (acute massive PE/PT/PTE) with overt RV dilatation
and RV systolic dysfunction.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
T22. A PDE5i is recommended in addition to anticoagulant treat-
ment for group 4b patients (chronic PE/PT/PTE).40,42
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.3.5 | Group 5 PH secondary to parasitic disease
(Dirofilaria or Angiostrongylus infection)
T23. The 2018 American Heartworm Society guidelines do not pro-
vide recommendations for PH-specific treatment. No peer-reviewed
studies have investigated PH-specific treatment solely in dogs with
heartworm disease. Treatment with a PDE5i may be considered for
dogs with Dirofilaria immitis infection.210,219
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
T24. In a small retrospective study of dogs with angiostrongylosis and
PH, treatmentwith sildenafil did not impact survival.162However, because
moderate to severe PH is recognized in approximately 15% of dogs with
Angiostrongylus vasorum infection, and these dogs have a worse prognosis
than thosewithout PH,162 treatment using a PDE5imay be considered.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
7.3.6 | Group 6 PH with multifactorial or unclear
mechanisms
Because group 6a disorders have multifactorial mechanisms, arise
from independent comorbid conditions, or both, it is critical that treat-
ment targets each underlying pathologic mechanism as outlined above
(treatment recommendations T2-T12). Because comorbid conditions
may independently fall into groups 1-5, the clinician also should be
familiar with when PH-specific treatments are recommended within
each group (treatment recommendations T13-T24) and integrate this
information to formulate a final treatment plan.
7.3.7 | Additional PH-specific treatments
In dogs with progressive disease or in those failing to respond when
dose-escalating PH-specific treatments described above have been used,
alternative or adjunctive treatments may be sought (Box 1). Insufficient
evidence is available at this time to recommend other treatments.
8 | GUIDELINES FOR LONG-TERM
MONITORING
Clinical experience suggests the prognosis of dogs with PH is variable
and related to the cause of PH. Unless a reversible cause of PH is
identified, dogs with a high probability of PH are likely to experience a
worse prognosis than dogs with same disease but with a low
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probability of PH. This was demonstrated in a large retrospective
study of dogs with MMVD, likely the most common cause of PH in
dogs.82 Right-sided heart failure secondary to PH also likely has a
worse prognosis. Factors such as cost of care, client financial
resources, and commitment to care, and the client's and attending cli-
nician's perception of PH (and its underlying cause) can affect survival
times, which makes it challenging to prognosticate for individual dogs
with PH. Regardless of the cause of PH, once PH-specific treatment is
initiated, patients should be monitored for improvement, static condi-
tion, or progression using consensus recommendations for monitoring
given below. Additionally, whenever possible, any identified underly-
ing disorder should be addressed and monitored simultaneously. Rec-
ommendations for monitoring underlying disorders are beyond the
scope of this consensus statement, and guidelines to supplement spe-
cific recommendations for monitoring underlying disorders (Box 2)
should be sought elsewhere.
A patient-specific and goal-oriented strategy for treatment is
recommended and necessitates careful monitoring with adjustment
of medications based on the magnitude of response and adverse
effects. Clinical improvement, thoracic radiography, pulse oximetry,
and arterial blood gases represent the most useful serial diagnostic
tests. Other means of monitoring include echocardiography, N termi-
nal pro-B-type natriuretic peptide, 6-minute walk test (6MWT), and
voluntary activity monitors. In people, the magnitude of PAP corre-
lates poorly with clinical signs and outcome and is not recommended
as a sole variable to guide therapeutic decisions.214 Similarly in dogs,
improvement in echocardiographic indices with PDE5i administra-
tion is sometimes40,42,84 but not always52,206,210 identified. In
comparison, the 6MWT in people is a simple, reproducible, and stan-
dardized means of assessing exercise capacity237 and is a critical pri-
mary endpoint used in most randomized controlled trials. In dogs,
the 6MWT has been used to discriminate healthy dogs from dogs
with respiratory disease.234,235 It also has been performed in dogs
with tricuspid regurgitation and MMVD.10 Voluntary activity moni-
tors84,210 allow assessment of exercise capacity for longer periods of
time (days to weeks) but are ethically challenging to use in compar-
ing baseline to treatment effect in patients requiring imminent
treatment.
M1. It is recommended that clinical assessments (degree and
direction of change in exercise tolerance, syncope, right-sided heart
failure, and respiratory rate and effort) play the major role in evalua-
tion of response to treatment and need for escalation of treatment.
Baseline assessments should be made to allow evaluation of treat-
ment response. In stable patients, clinical evaluation may be consid-
ered 2 weeks after starting or changing PH-specific treatment, every
3-6 months thereafter, and at any time when exacerbation of clinical
signs occurs. In unstable patients, clinical evaluation will be dictated
by the patient's needs. Questionnaires to assess owner-reported qual-
ity of life (eg, functional evaluation of cardiac health238) also may be
beneficial.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
M2. Although echocardiographic indices of PH may not always
correlate with clinical improvement or decompensation, echocardiog-
raphy may be repeated at the clinician's discretion. Regularly repeated
BOX 1 Unproven alternative or adjunct therapies that might be considered for use in dogs with pulmonary
hypertension
Pimobendan: Pimobendan is an oral PDE3i with positive inotropic and systemic vasodilatory properties. It has been shown to improve RV
systolic function following a single oral dose in healthy dogs.26 Although pimobendan has been suggested as a treatment for PH in
general,24,83,105,205,220 to date, there is no direct or clear evidence of its beneficial effects on pre-PH. Previously reported improvements in
estimated PAPs in dogs with MMVD might be related to its beneficial effect on lowering LA pressure221 and thus targeting postcapillary PH.
Further study is needed to help clarify pimobendan's role in pre-PH. Thus, the panel does not advocate for or against the use of
pimobendan as adjunct treatment in dogs with pre-PH.
Milrinone:Milrinone is an IV PDE3i. It has both PA vasodilating and positive inotropic properties. In experimental canine PH, milrinone
improved RV function222 and decreased mean PAP.223
Tyrosine kinase inhibitors (eg, toceranib, imatinib): Tyrosine kinase inhibitors (TKI) result in PA vasodilation by inhibiting the activation of
platelet derived growth factor by impeding phosphorylation of the platelet-derived growth factor receptor tyrosine kinase. In people,
specific TKI are effective at improving refractory PH224-228 but serious adverse events are common.228 In dogs, a single study demonstrated
imatinib reduced PAP in dogs diagnosed with PH secondary to LHD.229 Paradoxically, some TKI can induce PH in humans.230 Consideration
of and monitoring for contraindications and adverse events are indicated.
L-arginine: L-arginine is an amino acid that is essential, in conjunction with oxygen, to the production of NO. Oral administration increases
surrogate markers of NO in healthy dogs.231 Although no clinical studies in dogs have demonstrated the benefits of L-arginine in clinical
patients, 1 study in experimental canine acute PTE showed L-arginine and sildenafil together were not more beneficial than sildenafil
alone.232
In dogs, there is insufficient information in the literature and anecdotal experience with other PH-specific therapies used in humans (eg,
calcium channel blockers, endothelin antagonists, prostanoids, soluble guanylate cyclase stimulators, etc). No recommendations on the use
of these medications can be made at the current time.
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echocardiograms in clinically stable patients may not be necessary in
all dogs with PH.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
M3. Other complementary diagnostic tests may be considered to
guide treatment including thoracic imaging, pulse oximetry, arterial
blood gases, N terminal pro-B-type natriuretic peptide, 6MWT, and
activity monitors. Although it is recognized that a panel of data
reflecting patient status is likely to be superior to any single outcome
variable, the optimal means to evaluate patient status is, as yet,
unclear. Complementary diagnostic tests may be considered 2 weeks
after starting or changing PH-specific treatment, or in patients with
underlying disease impacting clinical signs, based on the clinician's
discretion.
• Consensus in 7/7 members of the panel and 5/5 advisory reviewers
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BOX 2 Specific considerations for monitoring underlying disorders
Group 1 PAH: Dogs in group 1a, 1b, 1c, 1d2, and 1d3 that have an antemortem diagnosis should follow consensus monitoring
recommendations above. In group 1d1, some congenital heart diseases may require additional monitoring to guide treatment (eg,
Eisenmenger's physiology should have a PCV or hematocrit when clinical signs are present to guide phlebotomy and administration of fluids
or hydroxyurea).54,177 Similar to dogs in group 1d1 and group 2, dogs in group 1’ might also develop acute pulmonary edema following
administration of a pulmonary artery vasodilator. Thus, if diagnosed antemortem (uncommon), appropriate monitoring (as previously
discussed) is warranted following administration of pulmonary artery vasodilators.
Group 2 PH secondary to left-sided cardiac disease: In group 2 dogs, monitoring recommendations often depend on where in the stage of
heart disease the dog is classified. If a dog develops postcapillary PH, the cardiac disease is more advanced. In all group 2 dogs, the main
points to monitor are the status of heart failure (primarily via thoracic radiography), and renal function and electrolyte status (both assessed
by a biochemical profile). Echocardiography may be indicated to assess for adverse complications of left-sided cardiac disease that can result
in decompensation of the patient, such as ruptured chordae tendineae, pericardial effusion secondary to an atrial tear, or the development
of an acquired atrial septal defect secondary to a tear of the interatrial septum. For dogs with an infectious component to the left-sided
cardiac disease, as in group 2a2 and 2c1b, monitoring for changes in the valve leaflets or chamber walls may be accomplished with
echocardiography. Serial analysis of cardiac troponin I might be useful in monitoring dogs with a presumptive diagnosis of myocarditis. The
reader is referred to the ACVIM consensus statement on MMVD in dogs161 and a comprehensive review of DCM in dogs233 for specific
monitoring recommendations for the underlying LHD.
Group 3 PH secondary to respiratory disease, hypoxia, or both: In many of the group 3 disorders (eg, 3a, 3b1b, 3b1e, 3b2, 3c), clinical signs
can guide titration of medications. In case of acute disease exacerbation or development of new clinical signs, repeating some of the initial
diagnostics (eg, imaging) may be warranted. Serial thoracic radiography can be performed to assess for improvement using glucocorticoids in
dogs with group 3b1b and 3b1e disorders and in dogs receiving antimicrobials in group 3b2. Dogs in group 3b1, particularly those with
fibrotic lung disease (3b1a) and chronic progressive ILDs (3b1d), can be monitored using measurement of arterial blood gas (or pulse
oximetry) or a 6MWT.234,235
Group 4 PH secondary to PE/PT/PTE: Duration of antithrombotic treatment depends if the underlying condition(s) have resolved (in which
case antithrombotic treatment should be discontinued following resolution of the thrombus) or are persistent (in which case antithrombotic
treatment should continue indefinitely).169 The reader is referred to recent consensus guidelines for specific anti-thrombotic monitoring and
weaning recommendations.169
Group 5 PH secondary to parasitic disease (heartworm or angiostrongylus infection): Confirmation of efficacy of Dirofilaria immitis
adulticidal treatment is most reliably performed using heartworm antigen testing.165 In dogs with angiostrongylosis, monitoring can be
performed by using antigen-based assays or molecular techniques on blood samples.236
Group 6 PH with multifactorial or unclear mechanisms: For group 6b dogs receiving targeted treatment, thoracic imaging every 1-3 months
to evaluate the size of the mass compressing the pulmonary arteries may be considered, with cross-sectional imaging (CT) likely more
sensitive to detect changes in mass size than thoracic radiography.
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